Drug · FAERS side-effect profile with label screen
Cinnamon side effects: what 3,300 FDA adverse event reports show
Drug class
Non-Standardized Food Allergenic Extract
FDA label (Established Pharmacologic Class) · compare the class
Brand names
Cinnamomum
openFDA label
Who reports
3,300 reports · 51% serious · 122 with death outcome · 63% female
openFDA FAERS counts, all years, deduplication not applied
Used for
See symptoms on front panel. Relieves diarrhea with gas and weakness
FDA label, Indications and Usage
Boxed warning
None in the current label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation.
Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)?
That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.
Causality screen of the 40 strongest signals
Lab value / disease marker 9No label text to screen 31
What the badges mean
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 225 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
Show:
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Flushing | 111 | 6.9 5.8–8.3ROR 7.1 · χ² 557 / p 2e-123 | 6.7 EB05 5.7 · IC025 +2.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.1 · 93% consumer | no trial data cached |
| Renal pain | 11 | 6.6 3.7–11.9ROR 6.6 · χ² 47 / p 4e-12 | 5.3 EB05 3.2 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.0 | no trial data cached |
| Tenderness | 10 | 6.1 3.3–11.3ROR 6.1 · χ² 38 / p 4e-10 | 4.9 EB05 2.8 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=9 | no trial data cached |
| Glycosylated haemoglobin increased | 24 | 6.1 4.1–9.0ROR 6.1 · χ² 96 / p 5e-23 | 5.5 EB05 3.9 · IC025 +1.8 3/3 methods agree | Lab value / disease marker | serious PRR 7.8 · ♀ 35% (drug 63%) · 82% consumer | no trial data cached |
| Hyperlipidaemia | 11 | 5.8 3.2–10.5ROR 5.8 · χ² 39 / p 2e-10 | 4.8 EB05 2.9 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.3 | no trial data cached |
| Gout | 16 | 5.7 3.5–9.2ROR 5.7 · χ² 57 / p 2e-14 | 4.9 EB05 3.2 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.4 | no trial data cached |
| Seasonal allergy | 12 | 5.4 3.1–9.5ROR 5.4 · χ² 39 / p 2e-10 | 4.5 EB05 2.8 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=6 | no trial data cached |
| Chronic kidney disease | 62 | 5.1 4.0–6.6ROR 5.2 · χ² 203 / p 2e-46 | 5.0 EB05 4.0 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.8 | no trial data cached |
| Flatulence (gas) | 45 | 5.1 3.8–6.8ROR 5.1 · χ² 143 / p 4e-33 | 4.8 EB05 3.7 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.0 · 78% consumer | no trial data cached |
| Rotator cuff syndrome | 10 | 4.9 2.7–9.2ROR 4.9 · χ² 28 / p 8e-8 | 4.1 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.8 | no trial data cached |
| Blood glucose abnormal | 14 | 4.8 2.8–8.1ROR 4.8 · χ² 38 / p 3e-10 | 4.2 EB05 2.7 · IC025 +1.2 3/3 methods agree | Lab value / disease marker | serious PRR 8.3 | no trial data cached |
| Balance disorder | 65 | 4.8 3.8–6.1ROR 4.8 · χ² 191 / p 1e-43 | 4.6 EB05 3.8 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.3 · 77% consumer | no trial data cached |
| Localised infection | 18 | 4.7 3.0–7.5ROR 4.7 · χ² 49 / p 1e-12 | 4.3 EB05 2.9 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.4 | no trial data cached |
| Cold sweat | 13 | 4.7 2.7–8.1ROR 4.7 · χ² 34 / p 3e-9 | 4.1 EB05 2.6 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.1 | no trial data cached |
| Blood triglycerides increased | 13 | 4.7 2.7–8.0ROR 4.7 · χ² 34 / p 3e-9 | 4.1 EB05 2.5 · IC025 +1.1 3/3 methods agree | Lab value / disease marker | serious PRR 3.2 | no trial data cached |
| Carpal tunnel syndrome | 10 | 4.5 2.4–8.4ROR 4.5 · χ² 24 / p 5e-7 | 3.8 EB05 2.3 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.0 | no trial data cached |
| Urinary incontinence | 21 | 4.5 2.9–6.9ROR 4.5 · χ² 54 / p 1e-13 | 4.1 EB05 2.9 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.5 | no trial data cached |
| Tendonitis | 11 | 4.5 2.5–8.1ROR 4.5 · χ² 26 / p 1e-7 | 3.9 EB05 2.3 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.1 | no trial data cached |
| Blood pressure abnormal | 14 | 4.5 2.7–7.6ROR 4.5 · χ² 35 / p 2e-9 | 4.0 EB05 2.5 · IC025 +1.1 3/3 methods agree | Lab value / disease marker | serious PRR 5.3 | no trial data cached |
| Sinus disorder | 14 | 4.5 2.7–7.6ROR 4.5 · χ² 35 / p 2e-9 | 4.0 EB05 2.5 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.2 | no trial data cached |
| Sciatica | 11 | 4.4 2.4–8.0ROR 4.4 · χ² 26 / p 2e-7 | 3.8 EB05 2.3 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.3 | no trial data cached |
| Blood urine present | 13 | 4.3 2.5–7.5ROR 4.3 · χ² 30 / p 2e-8 | 3.8 EB05 2.4 · IC025 +1.0 3/3 methods agree | Lab value / disease marker | serious PRR 4.8 | no trial data cached |
| Type 2 diabetes mellitus | 23 | 4.3 2.9–6.5ROR 4.4 · χ² 56 / p 4e-14 | 4.0 EB05 2.8 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.7 | no trial data cached |
| Sleep apnoea syndrome | 13 | 4.3 2.5–7.4ROR 4.3 · χ² 30 / p 2e-8 | 3.8 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.5 | no trial data cached |
| Haemorrhoids | 13 | 4.2 2.5–7.3ROR 4.2 · χ² 29 / p 4e-8 | 3.7 EB05 2.3 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.5 | no trial data cached |
| Hot flush (hot flashes) | 49 | 4.1 3.1–5.5ROR 4.2 · χ² 114 / p 8e-27 | 4.0 EB05 3.1 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.8 · 85% consumer | no trial data cached |
| Full blood count decreased | 13 | 4.1 2.4–7.1ROR 4.1 · χ² 27 / p 8e-8 | 3.6 EB05 2.3 · IC025 +0.9 3/3 methods agree | Lab value / disease marker | serious PRR 5.1 | no trial data cached |
| Neuropathy peripheral (nerve damage in hands/feet) | 60 | 4.0 3.1–5.2ROR 4.1 · χ² 134 / p 2e-31 | 3.9 EB05 3.2 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.8 | no trial data cached |
| Blood glucose decreased | 30 | 4.0 2.8–5.6ROR 4.0 · χ² 63 / p 8e-16 | 3.7 EB05 2.8 · IC025 +1.3 3/3 methods agree | Lab value / disease marker | serious PRR 3.7 · 75% consumer | no trial data cached |
| Gastrooesophageal reflux disease (acid reflux) | 49 | 3.9 2.9–5.1ROR 3.9 · χ² 102 / p 2e-24 | 3.8 EB05 3.0 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.3 · 75% consumer | no trial data cached |
| Restless legs syndrome | 11 | 3.8 2.1–6.9ROR 3.8 · χ² 20 / p 3e-6 | 3.4 EB05 2.0 · IC025 +0.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.2 | no trial data cached |
| Upper limb fracture | 12 | 3.8 2.2–6.7ROR 3.8 · χ² 22 / p 1e-6 | 3.4 EB05 2.1 · IC025 +0.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.5 | no trial data cached |
| Blood glucose increased | 111 | 3.7 3.1–4.5ROR 3.8 · χ² 221 / p 3e-50 | 3.7 EB05 3.1 · IC025 +1.6 3/3 methods agree | Lab value / disease marker | serious PRR 5.0 · 76% consumer | no trial data cached |
| Dysstasia | 17 | 3.7 2.3–5.9ROR 3.7 · χ² 31 / p 2e-8 | 3.4 EB05 2.3 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.1 | no trial data cached |
| Feeling cold | 16 | 3.6 2.2–5.9ROR 3.7 · χ² 28 / p 6e-8 | 3.3 EB05 2.2 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.9 | no trial data cached |
| Diabetes mellitus inadequate control | 10 | 3.6 1.9–6.7ROR 3.6 · χ² 16 / p 3e-5 | 3.2 EB05 1.9 · IC025 +0.6 | No label text to screen label has no adverse-reaction text | serious PRR 3.8 | no trial data cached |
| Eye pain | 31 | 3.6 2.5–5.1ROR 3.6 · χ² 55 / p 7e-14 | 3.4 EB05 2.5 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.3 · 87% consumer | no trial data cached |
| Impaired work ability | 12 | 3.6 2.0–6.3ROR 3.6 · χ² 20 / p 5e-6 | 3.2 EB05 2.0 · IC025 +0.7 | No label text to screen label has no adverse-reaction text | serious PRR 3.4 | no trial data cached |
| Blood cholesterol increased | 26 | 3.5 2.4–5.2ROR 3.6 · χ² 45 / p 1e-11 | 3.4 EB05 2.4 · IC025 +1.1 3/3 methods agree | Lab value / disease marker | serious PRR 4.7 | no trial data cached |
| Gastroenteritis viral | 10 | 3.5 1.9–6.5ROR 3.5 · χ² 16 / p 4e-5 | 3.1 EB05 1.8 · IC025 +0.6 | No label text to screen label has no adverse-reaction text | serious PRR 3.8 | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Arthralgia (joint pain) | 159 | 2.4 2.1–2.8ROR 2.5 · χ² 136 / p 1e-31 | 2.4 EB05 2.1 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.2 | no trial data cached |
| Blood glucose increased | 111 | 3.7 3.1–4.5ROR 3.8 · χ² 221 / p 3e-50 | 3.7 EB05 3.1 · IC025 +1.6 3/3 methods agree | Lab value / disease marker | serious PRR 5.0 · 76% consumer | no trial data cached |
| Flushing | 111 | 6.9 5.8–8.3ROR 7.1 · χ² 557 / p 2e-123 | 6.7 EB05 5.7 · IC025 +2.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.1 · 93% consumer | no trial data cached |
| Feeling abnormal | 99 | 2.6 2.2–3.2ROR 2.7 · χ² 98 / p 2e-23 | 2.6 EB05 2.2 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.9 | no trial data cached |
| Peripheral swelling | 77 | 3.2 2.6–4.0ROR 3.2 · χ² 114 / p 6e-27 | 3.1 EB05 2.6 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.6 | no trial data cached |
| Paraesthesia (tingling/numbness) | 72 | 2.9 2.3–3.6ROR 2.9 · χ² 88 / p 3e-21 | 2.9 EB05 2.3 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.5 · 84% consumer | no trial data cached |
| Myalgia (muscle pain) | 70 | 2.6 2.1–3.3ROR 2.7 · χ² 69 / p 5e-17 | 2.6 EB05 2.1 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.3 · 72% consumer | no trial data cached |
| Memory impairment | 65 | 3.0 2.4–3.8ROR 3.0 · χ² 85 / p 1e-20 | 3.0 EB05 2.4 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.8 · 75% consumer | no trial data cached |
| Balance disorder | 65 | 4.8 3.8–6.1ROR 4.8 · χ² 191 / p 1e-43 | 4.6 EB05 3.8 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.3 · 77% consumer | no trial data cached |
| Drug dose omission | 63 | 2.4 1.9–3.0ROR 2.4 · χ² 50 / p 9e-13 | 2.4 EB05 1.9 · IC025 +0.8 | Reporting / coding artifact | serious PRR 5.3 | no trial data cached |
| Chronic kidney disease | 62 | 5.1 4.0–6.6ROR 5.2 · χ² 203 / p 2e-46 | 5.0 EB05 4.0 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.8 | no trial data cached |
| Injection site pain (pain where injected) | 60 | 1.3 1.0–1.6ROR 1.3 · χ² 3 / p 0.044 | 1.3 EB05 1.0 · IC025 -0.1 PRR-only: not supported by EBGM or IC | No label text to screen label has no adverse-reaction text | serious PRR 2.0 · 85% consumer | no trial data cached |
| Neuropathy peripheral (nerve damage in hands/feet) | 60 | 4.0 3.1–5.2ROR 4.1 · χ² 134 / p 2e-31 | 3.9 EB05 3.2 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.8 | no trial data cached |
| Vision blurred (blurred vision) | 56 | 2.6 2.0–3.4ROR 2.6 · χ² 54 / p 1e-13 | 2.6 EB05 2.1 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.2 · 77% consumer | no trial data cached |
| Sinusitis | 56 | 3.5 2.7–4.5ROR 3.5 · χ² 96 / p 6e-23 | 3.4 EB05 2.7 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.6 | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Cinnamon?
In FDA FAERS, the most frequently co-reported reaction terms for Cinnamon are arthralgia, blood glucose increased, flushing, feeling abnormal, peripheral swelling, paraesthesia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Cinnamon have an FDA boxed warning?
No. The FDA label retrieved for Cinnamon has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Cinnamon causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 163b7c61-4580-0ff7-e063-6294a90a3689, effective 20240416; matched on
openfda.generic_name.exact:"CINNAMON") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 265 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.